Cargando…
Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
BACKGROUND AND PURPOSE: Sickle cell disease (SCD) is strongly linked to stroke across all haplotypes in the pediatric population. Transcranial Doppler (TCD) ultrasound is known to identify the highest risk group in African-Americans who need to receive and stay on blood transfusions, but it is uncle...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Stroke Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060272/ https://www.ncbi.nlm.nih.gov/pubmed/24949316 http://dx.doi.org/10.5853/jos.2014.16.2.97 |
_version_ | 1782321349598904320 |
---|---|
author | Bavarsad Shahripour, Reza Mortazavi, Martin M. Barlinn, Kristian Keikhaei, Bijan Mousakhani, Hadi Azarpazhooh, Mahmoud Reza Oghbaee, Morteza Sajedi, Seyed Aidin Kepplinger, Jessica Tubbs, R. Shane Albright, Karen C. Alexandrov, Andrei V. |
author_facet | Bavarsad Shahripour, Reza Mortazavi, Martin M. Barlinn, Kristian Keikhaei, Bijan Mousakhani, Hadi Azarpazhooh, Mahmoud Reza Oghbaee, Morteza Sajedi, Seyed Aidin Kepplinger, Jessica Tubbs, R. Shane Albright, Karen C. Alexandrov, Andrei V. |
author_sort | Bavarsad Shahripour, Reza |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Sickle cell disease (SCD) is strongly linked to stroke across all haplotypes in the pediatric population. Transcranial Doppler (TCD) ultrasound is known to identify the highest risk group in African-Americans who need to receive and stay on blood transfusions, but it is unclear if the same flow velocity cut-offs can be applied to the Iranian population. We aimed to evaluate baseline TCD findings in Iranian children with SCD and no prior strokes. METHODS: Children with genetically confirmed SCD (Arabian haplotype, homozygote) and without SCD (controls) were prospectively recruited from pediatric outpatient clinic over a period of 9 months. We performed TCD in both groups to determine flow velocities in the middle cerebral (MCA) and terminal internal carotid arteries (TICA). RESULTS: Of 74 screened children, 60 met the inclusion/exclusion criteria (62% female; mean age 10±4 years). Baseline characteristics did not differ between the cases and controls, except hemoglobin (Hb) which was significantly lower in the SCD group (P<0.001). The right MCA TAMM (Time Averaged Maximum Mean) was significantly higher than in controls (125+5.52 cm/s vs. 92.5+1.63 cm/s, P<0.001). Left MCA did not show differences. The TICA TAMM was also different between cases and controls (P<0.05). CONCLUSIONS: Among Iranian children with asymptomatic SCD and without receiving recent transfusion TCD velocities are higher as compared to healthy controls but appear much lower than those observed in STOP (Stroke Prevention Trial in Sickle Cell Anemia) studies. We hypothesize that some children at high risk may be present with velocities lower than 170-200 cm/s thresholds. A prospective validation of ethnicity-specific prognostic criteria is warranted. |
format | Online Article Text |
id | pubmed-4060272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Korean Stroke Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-40602722014-06-19 Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? Bavarsad Shahripour, Reza Mortazavi, Martin M. Barlinn, Kristian Keikhaei, Bijan Mousakhani, Hadi Azarpazhooh, Mahmoud Reza Oghbaee, Morteza Sajedi, Seyed Aidin Kepplinger, Jessica Tubbs, R. Shane Albright, Karen C. Alexandrov, Andrei V. J Stroke Original Article BACKGROUND AND PURPOSE: Sickle cell disease (SCD) is strongly linked to stroke across all haplotypes in the pediatric population. Transcranial Doppler (TCD) ultrasound is known to identify the highest risk group in African-Americans who need to receive and stay on blood transfusions, but it is unclear if the same flow velocity cut-offs can be applied to the Iranian population. We aimed to evaluate baseline TCD findings in Iranian children with SCD and no prior strokes. METHODS: Children with genetically confirmed SCD (Arabian haplotype, homozygote) and without SCD (controls) were prospectively recruited from pediatric outpatient clinic over a period of 9 months. We performed TCD in both groups to determine flow velocities in the middle cerebral (MCA) and terminal internal carotid arteries (TICA). RESULTS: Of 74 screened children, 60 met the inclusion/exclusion criteria (62% female; mean age 10±4 years). Baseline characteristics did not differ between the cases and controls, except hemoglobin (Hb) which was significantly lower in the SCD group (P<0.001). The right MCA TAMM (Time Averaged Maximum Mean) was significantly higher than in controls (125+5.52 cm/s vs. 92.5+1.63 cm/s, P<0.001). Left MCA did not show differences. The TICA TAMM was also different between cases and controls (P<0.05). CONCLUSIONS: Among Iranian children with asymptomatic SCD and without receiving recent transfusion TCD velocities are higher as compared to healthy controls but appear much lower than those observed in STOP (Stroke Prevention Trial in Sickle Cell Anemia) studies. We hypothesize that some children at high risk may be present with velocities lower than 170-200 cm/s thresholds. A prospective validation of ethnicity-specific prognostic criteria is warranted. Korean Stroke Society 2014-05 2014-05-30 /pmc/articles/PMC4060272/ /pubmed/24949316 http://dx.doi.org/10.5853/jos.2014.16.2.97 Text en Copyright © 2014 Korean Stroke Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Bavarsad Shahripour, Reza Mortazavi, Martin M. Barlinn, Kristian Keikhaei, Bijan Mousakhani, Hadi Azarpazhooh, Mahmoud Reza Oghbaee, Morteza Sajedi, Seyed Aidin Kepplinger, Jessica Tubbs, R. Shane Albright, Karen C. Alexandrov, Andrei V. Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? |
title | Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? |
title_full | Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? |
title_fullStr | Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? |
title_full_unstemmed | Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? |
title_short | Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? |
title_sort | can stop trial velocity criteria be applied to iranian children with sickle cell disease? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060272/ https://www.ncbi.nlm.nih.gov/pubmed/24949316 http://dx.doi.org/10.5853/jos.2014.16.2.97 |
work_keys_str_mv | AT bavarsadshahripourreza canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT mortazavimartinm canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT barlinnkristian canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT keikhaeibijan canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT mousakhanihadi canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT azarpazhoohmahmoudreza canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT oghbaeemorteza canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT sajediseyedaidin canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT kepplingerjessica canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT tubbsrshane canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT albrightkarenc canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease AT alexandrovandreiv canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease |